WUXI BIOLOGICS CAYMAN INC USD00000083 144A REG S WXIBF
COM · Common Stock · CUSIP G97008117
2
institutional holders
+1 vs Q3 2021
8.3m
shares reported held*
$98.6mreported value*
1 new
0 added
1 reduced
0 sold out
net sold ≈ $9.2m (-778.6k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $11.87.
Trends to Q4 2021
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q4 2020 | 1 |
| Q1 2021 | 1 |
| Q2 2021 | 1 |
| Q3 2021 | 1 |
| Q4 2021 | 2 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2021 | 1 | 0 |
| Q2 2021 | 0 | 1 |
| Q3 2021 | 0 | 1 |
| Q4 2021 | 1 | 1 |
Biggest buyers
| Laird Norton Wetherby Trust Company, LLC | New | +10.5k |
Biggest sellers
| GILDER GAGNON HOWE & CO LLC | Reduced | -789.1k |
Holders, Q4 2021
| Manager | Shares | Change |
|---|---|---|
| GILDER GAGNON HOWE & CO LLC 0.56% of their portfolio | 8.3m $98.4m | Reduced -789.1k |
| Laird Norton Wetherby Trust Company, LLC 0.01% of their portfolio | 10.5k $124.0k | New |